YS Biopharma Reports Positive Results in Rabies Vaccine Trial
Global biopharmaceutical company, YS Biopharma (Nasdaq: YS) has announced positive interim results from its ongoing Phase 3 clinical trial of a next-generation PIKA Rabies Vaccine. The vaccine utilizes YS Biopharma’s proprietary PIKA adjuvant technology and is designed to produce a more robust immune response in an accelerated timespan compared to existing rabies vaccines.
The interim results indicate that the PIKA Rabies Vaccine has successfully met the trial’s primary endpoints. The company believes its vaccine candidate has the potential to achieve best-in-class accelerated protection and meet the World Health Organization’s (WHO) goal of a one-week rabies vaccine regimen to replace the conventional three- or four-week regimens.
Dr. Zenaida Mojares, Chief Medical Officer of YS Biopharma, commented, “The interim results of the pivotal Phase 3 Trial provide compelling evidence of the robust immunogenicity and favorable safety profile of the PIKA Rabies Vaccine. By providing a shortened treatment regimen without sacrificing safety or quality, the PIKA Rabies Vaccine has the potential to improve rabies treatment and compliance.
“At present, the long and inconvenient regimen length for existing rabies vaccines represents a major barrier to treatment completion, and we are eager to see how the enhanced speed of the PIKA Rabies Vaccine might have a positive impact on patients. We are proud of our team for the hard work and dedication which got us to this point, and we are excited to see how our advances will contribute to the ongoing global fight against rabies.”
YS Biopharma’s pivotal registration Phase 3 Trial is a randomized, comparator-controlled, double-blind, multicenter trial which includes 4,500 participants from the Philippines and Pakistan.
The PIKA Rabies Vaccine has been granted orphan drug designation by the FDA for prevention of rabies virus infection including post-exposure prophylaxis (PEP) for rabies.
About YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit www.ysbiopharma.com.
